Pelthos signs benefit manager agreement expanding patient access to ZELSUVMI

Pelthos Therapeutics (PTHS) announced it has signed its first commercial agreement to expand patient access for ZELSUVMI topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older. Pelthos has entered into an agreement with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers in the United States. The PBM manages prescription drug benefits for more than 20 million covered lives, and the formulary inclusion updates for ZELSUVMI started on December 1, 2025. “Partnering with a national pharmacy benefit manager is another important milestone in our efforts to achieve increased commercial coverage for ZELSUVMI,” said Scott Plesha, CEO of Pelthos. “This new partnership will allow an important treatment option to be included in more coverage and distribution networks, thereby improving access for patients and caregivers who are seeking an at-home treatment for molluscum contagiosum.”